These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15861730)

  • 1. [Hematopoietic stem cell transplantation].
    Morishima Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():690-4. PubMed ID: 15861730
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunology. A perfect mismatch.
    Kärre K
    Science; 2002 Mar; 295(5562):2029-31. PubMed ID: 11896262
    [No Abstract]   [Full Text] [Related]  

  • 3. [Graft vs. host disease and graft vs. leukemia/tumor effect].
    Okamoto S
    Nihon Rinsho; 2003 Sep; 61(9):1484-7. PubMed ID: 14515713
    [No Abstract]   [Full Text] [Related]  

  • 4. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactive killer cells: hindrance and help for haematopoietic transplants.
    Parham P; McQueen KL
    Nat Rev Immunol; 2003 Feb; 3(2):108-22. PubMed ID: 12563295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients.
    Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
    Eur J Haematol; 2007 Apr; 78(4):338-46. PubMed ID: 17378893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graft engineering.
    Noga SJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):15-21. PubMed ID: 10877046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic hematopoietic stem cell transplantation for solid tumors].
    Kanda Y
    Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931
    [No Abstract]   [Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
    Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
    Ruggeri L; Mancusi A; Burchielli E; Perruccio K; Aversa F; Martelli MF; Velardi A
    Semin Cancer Biol; 2006 Oct; 16(5):404-11. PubMed ID: 16916611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
    Moretta A; Locatelli F; Moretta L
    Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GVHD and GVL].
    Teshima T
    Rinsho Ketsueki; 2009 Oct; 50(10):1407-19. PubMed ID: 19915349
    [No Abstract]   [Full Text] [Related]  

  • 16. The history and future prospective of haplo-identical stem cell transplantation.
    Handgretinger R; Lang P
    Cytotherapy; 2008; 10(5):443-51. PubMed ID: 18615344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation.
    Ruggeri L; Capanni M; Mancusi A; Martelli MF; Velardi A
    Transpl Immunol; 2005 Aug; 14(3-4):203-6. PubMed ID: 15982564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)].
    Tanaka J
    Nihon Rinsho; 2003 Sep; 61(9):1512-9. PubMed ID: 14515717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.